A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR)

Charles L. Bennett; David M. Spiegel; Iain C. Macdougall; LeAnn Norris; Zaina P. Qureshi; Oliver Sartor; Stephen Y. Lai; Martin S. Tallman; Dennis W. Raisch; Sheila Weiss Smith; Samuel Silver; Alanna S. Murday; James O. Armitage; David Goldsmith

doi:10.1055/s-0032-1328884

Seminars in Thrombosis and Hemostasis, Inhaltsverzeichnis

Semin Thromb Hemost 2012; 38(08): 783-796
DOI: 10.1055/s-0032-1328884

Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

A Review of Safety, Efficacy, and Utilization of Erythropoietin, Darbepoetin, and Peginesatide for Patients with Cancer or Chronic Kidney Disease: A Report from the Southern Network on Adverse Reactions (SONAR)

Charles L. Bennett

¹The Southern Network on Adverse Reactions (SONAR) project, the South Carolina Center of Economic Excellence for Medication Safety, the South Carolina College of Pharmacy, Columbia, South Carolina

²Arnold School of Public Health of the University of South Carolina, Columbia, South Carolina

³WJB Dorn VA Medical Center, Columbia, South Carolina

⁴Hollings Cancer Center of the Medical University of South Carolina, Charleston, South Carolina

,

David M. Spiegel

⁵Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado

,

Iain C. Macdougall

⁶Department of Renal Medicine, King's College Hospital, London, United Kingdom

,

LeAnn Norris

¹The Southern Network on Adverse Reactions (SONAR) project, the South Carolina Center of Economic Excellence for Medication Safety, the South Carolina College of Pharmacy, Columbia, South Carolina

³WJB Dorn VA Medical Center, Columbia, South Carolina

,

Zaina P. Qureshi

¹The Southern Network on Adverse Reactions (SONAR) project, the South Carolina Center of Economic Excellence for Medication Safety, the South Carolina College of Pharmacy, Columbia, South Carolina

²Arnold School of Public Health of the University of South Carolina, Columbia, South Carolina

³WJB Dorn VA Medical Center, Columbia, South Carolina

,

Oliver Sartor

⁷Departments of Urology and Oncology and the Tulane University Cancer Center, New Orleans, Louisiana

,

Stephen Y. Lai

⁸University of Texas M.D. Anderson Cancer Center, Department of Head and Neck Surgery, Houston, Texas

,

Martin S. Tallman

⁹Memorial Sloan-Kettering Cancer Center, New York, New York

,

Dennis W. Raisch

¹⁰University of New Mexico College of Pharmacy, Albuquerque, New Mexico

,

Sheila Weiss Smith

¹¹Center for Drug Safety, University of Maryland School of Pharmacy, Baltimore, Maryland

,

Samuel Silver

¹²University of Michigan Medical School, Ann Arbor, Michigan

,

Alanna S. Murday

¹The Southern Network on Adverse Reactions (SONAR) project, the South Carolina Center of Economic Excellence for Medication Safety, the South Carolina College of Pharmacy, Columbia, South Carolina

³WJB Dorn VA Medical Center, Columbia, South Carolina

,

James O. Armitage

¹³Department of Internal Medicine, University of Nebraska College of Medicine, Omaha, Nebraska

,

David Goldsmith

¹⁴Guy's and St. Thomas National Health Service Foundation Hospital, London, United Kingdom

› Institutsangaben

Abstract

The erythropoiesis-stimulating agents (ESAs) erythropoietin and darbepoetin prevent transfusions among chemotherapy-associated anemia patients. Clinical trials, meta-analyses, and guidelines identify mortality, tumor progression, and venous thromboembolism (VTE) risks with ESA administration in this setting. Product labels advise against administering ESAs with potentially curative chemotherapy (United States) or to conduct risk–benefit assessments (Europe/Canada). Since 2007, fewer chemotherapy-associated anemia patients in the United States and Europe receive ESAs. ESAs and the erythropoietin receptor agonist peginesatide prevent transfusions among chronic kidney disease (CKD) patients; clinical trials, guidelines, and meta-analyses demonstrate myocardial infarction, stroke, VTE, or mortality risks with ESAs targeting high hemoglobin levels. U.S. labels recommend administering ESAs or peginesatide at doses sufficient to prevent transfusions among dialysis CKD patients. For dialysis CKD patients, Canadian and European labels recommend targeting hemoglobin levels of 10 to 12 g/dL and 11 to 12 g/dL, respectively, with ESAs. ESA utilization for dialysis CKD patients has decreased in the United States.

Keywords

darbepoetin - epoetin - erythropoiesis-stimulating agents - peginesatide

Volltext

Referenzen

References
1 Besarab A, Bolton WK, Browne JK , et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339 (9) 584-590
2 Pfeffer M, Burdmann EA, Cooper DE , et al. A trial of darbepoetin-alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361: 1-14
3 FDA. Briefing Document on Peginesatide for the Oncologic Drug Advisory Committee (ODAC) December 7, 2011. Available at: http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/oncologicdrugsadvisorycommittee/ucm282292.pdf . Accessed April 4, 2012
4 Leyland-Jones B. BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4 (8) 459-460
5 Henke M, Laszig R, Rübe C , et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362 (9392) 1255-1260
6 Bennett CL, Silver SM, Djulbegovic B , et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008; 299 (8) 914-924
7 Wilson J, Yao GL, Raftery J , et al. A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007; 11 (13) 1-202 , iii–iv
8 Bohlius J, Schmidlin K, Brillant C , et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373 (9674) 1532-1542
9 Glaspy J, Crawford J, Vansteenkiste J , et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102 (2) 301-315
10 Tonelli M, Hemmelgarn B, Reiman T , et al. Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 2009; 180 (11) E62 –E71
11 Epogen package insert. Amgen, Inc. 2007. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103234s5158ppi.pdf . Accessed May 2, 2012
12 FDA Advisory Committee Briefing Document. Reassessment of the risks of erythropoiesis-stimulating agents (ESAs) administered for the treatment of anemia associated with chronic renal failure. Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee. September 11, 2007. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4315b1-01-FDA.pdf . Accessed May 2, 2012
13 Rizzo JD, Somerfield MR, Hagerty KL , et al; American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008; 26 (1) 132-149
14 Meeting Briefing Document ODAC. Epoetin alfa and darbepoetin. 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-05-amgen.pdf . Accessed May 2, 2012
15 Epogen FDA. (Epoetin alfa) For injection package insert. 2008. Available at: http://www.fda.gov/cder/foi/label/2008/103234s5195sPI.pdf . Accessed May 2, 2012
16 Patient Medication Guide FDA. Epogen (Epoetin alfa). 2008. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103234s5195Medguide.pdf . Accessed May 2, 2012
17 National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: cancer and chemotherapy–induced anemia. V.1.2009. Available at: http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf . Accessed May 2, 2012
18 US FDA. FDA approves a risk evaluation and mitigation strategy (REMS) to ensure the safe use of erythropoiesis-stimulating agents (ESAs). 2010. Available at: http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm200847.htm . Accessed May 2, 2012
19 Rizzo JD, Brouwers M, Hurley P , et al; American Society of Clinical Oncology; American Society of Hematology. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28 (33) 4996-5010
20 European Medicines Agency. Public Statement. Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease. October 2007. Available at: http://www.emea.europa.eu/pdfs/human/press/pus/49618807en.pdf . Accessed May 2, 2012
21 Aapro M, Spivak JL. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 2009; 14 (Suppl. 01) 6-15
22 Medicines and Healthcare products Regulatory Agency (MHRA). Conclusions from the Committee for Medicinal Products for Human Use (CHMP) – Review of safety of erythropoiesis stimulating agents (ESAs) in patients with anaemia resulting from renal insufficiency or chemotherapy in cancer patients. 2008. Available at: http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con023076.pdf . Accessed May 2, 2012
23 National Institute for Health and Clinical Excellence (NICE). Technology Appraisal Guidance-Epoetin Alfa, Epoetin Beta, and Darboepoetin Alfa for Cancer Treatment Induced Anaemia. London, UK: National Institute for Health and Clinical Excellence (NICE); 2008. . Available at: http://www.nice.org.uk/nicemedia/pdf/TA142Guidance.pdf . Accessed
24 Health Canada. Important safety information and new prescribing information for the erythropoiesis-stimulating agents, aranesp (darbepoetin alfa) and EPREX (epoetin alfa). 2007. . Available at: http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/medeff/advisories-avis/public/2007/aranesp_eprex_pc-cp-eng.pdf . Accessed May 2, 2012
25 Tonelli M, Lloyd A, Lee H , et al. Overview of systematic review and economic evaluation of erythropoiesis stimulating agents for anemia of cancer or of chemotherapy (technology overview number 51). Ottawa: Canadian Agency for Drugs and Technologies in Health; 2009
26 Singh AK, Szczech L, Tang KL , et al; CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355 (20) 2085-2098
27 Drüeke TB, Locatelli F, Clyne N , et al; CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355 (20) 2071-2084
28 Cotter DJ, Stefanik K, Zhang Y, Thamer M, Scharfstein D, Kaufman J. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. J Clin Epidemiol 2004; 57 (10) 1086-1095
29 KDOQI. KDOQI clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 Update of Hemoglobin Target. Am J Kidney Dis 2007; 50 (3) 471-530
30 Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369 (9559) 381-388
31 Zhang Y, Thamer M, Kaufman JS, Cotter DJ, Hernán MA. High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes. Kidney Int 2011; 80 (6) 663-669
32 KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. Am J Kidney Dis 2007; 50 (3) 471-530
33 US FDA. Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee meeting. 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/transcripts/2008-4390t1-part1.PDF . Accessed May 2, 2012
34 Epogen FDA. (Epoetin alfa) For injection package insert. November 19, 2008. Available at: http://www.fda.gov/cder/foi/label/2008/103234s5195sPI.pdf . Accessed May 2, 2012
35 US FDA. Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee meeting. 2010. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM238530.pdf . Accessed May 2, 2012
36 US FDA. Center for Drug Evaluation and Research. Cardiovascular and Renal Drugs Advisory Committee meeting. 2011. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM256586.pdf . Accessed May 2, 2012
37 Epogen package insert FDA. 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf . Accessed May 2, 2012
38 Epogen/Procrit label. June 24, 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/103234Orig1s5166_103234Orig1s5266lbl.pdf . Accessed May 2, 2012
39 EMA summary of product characteristics. Abseamed (Epoetin alfa). October 12, 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation/human/000726/WC500028289.pdf . Accessed April 4, 2012
40 Locatelli F, Aljama P, Canaud B , et al. Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010; 25 (9) 2846-2850
41 National Institute for Health and Clinical Excellence (NICE). Appraisal Consultation Document – Erythropoietin for anaemia induced by cancer treatment. 2011. http://www.nice.org.uk/guidance/index.jsp?action=article&r=true&o=34940 . Accessed May 2, 2012
42 Manns BJ, White CT, Madore F , et al. Introduction to the Canadian Society of Nephrology clinical practice guidelines for the management of anemia associated with chronic kidney disease. Kidney Int Suppl 2008; (110) S1-S3
43 Report T. Canadian Agency for Drugs and Technology in Health. Erythropoiesis-stimulating agents for anemia of chronic kidney disease: systematic review and economic evaluation. 2009. Available at: http://www.cadth.ca/media/pdf/H0468_Erythropoiesis-stimulating_agents_tr_e.pdf . Accessed May 2, 2012
44 Bennett CL, McKoy JM, Henke M , et al. Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) 2010; 24 (3) 260-268
45 McFarlane PA, Pisoni RL, Eichleay MA, Wald R, Port FK, Mendelssohn D. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 2010; 78 (2) 215-223
46 Regidor D, McClellan WM, Kewalramani R, Sharma A, Bradbury BD. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. Nephrol Dial Transplant 2011; 26 (5) 1583-1591
47 Goldsmith DJ, Covic AC. Significant further evidence to bolster the link between epoetin and strokes in chronic kidney disease and cancer. Kidney Int 2011; 80 (3) 237-239
48 Palmer SC, Navaneethan SD, Craig JC , et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 2010; 153 (1) 23-33
49 Medical Technology and Practice Patterns Institute (MTPPI). Citizen's petition. 2009. Available at: http://www.mtppi.org/new/FDA-2009-P-0426-0001.pdf . Accessed May 2, 2012
50 Cancer Care Ontario. Epoetin alfa (Eprex) Janseen Ortho Formulary. Available at: http://www.cancercare.on.ca/search/default.aspx?q=formulary%20erythropoietin&type=0,6-76,6-40484|-1,1377-78 . Accessed May 2, 2012
51 EMA. Manufacturer's label. Annex II. 2007. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000726/WC500028282.pdf . Accessed May 2, 2012
52 Medical Technology and Practice Patterns Institute (MTPPI). Citizen's petition. 2009. Available at: http://www.mtppi.org/new/FDA-2009-P-0426-0001.pdf . Accessed May 2, 2012